Asston Pharmaceu (544445)
Score breakdown: P/E: 2/3 · ROCE: 2/2 · Growth: 2/2 · Dividend: 0/1
Key Financials
| Current Price | ₹85 |
| Market Cap | ₹72.36 Cr |
| P/E Ratio | 13.58 |
| ROCE | 36.62% |
| ROE | —% |
| Dividend Yield | 0% |
| Profit Growth | 77.89% |
| Debt/Equity | — |
| Sales Growth | -3.44% |
| Sector | Pharmaceuticals & Biotechnology |
AI Analysis
AI-generated, general educational analysis — not personal investment advice.
Ben Graham taught me that price is what you pay, but value is what you get. At ₹85, Asston Pharmaceu has a market cap of only ₹72 crore and a P/E of 13.58. On the surface, that seems reasonably priced. But the latest quarter reminds me why a cheap multiple can be a trap: sales of ₹15 crore and net profit of effectively zero. A company that cannot earn a current quarterly profit is hard for me to value as a long-term owner.
The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer